# A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

> **NCT00282308** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 103 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Methotrexate
- **DRUG:** Methylprednisone
- **BIOLOGICAL:** C. albicans
- **BIOLOGICAL:** Tetanus toxoid adsorbed booster vaccine
- **BIOLOGICAL:** 23-valent pneumococcal polysaccharide vaccine
- **BIOLOGICAL:** Keyhole limpet hemocyanin

## Key facts

- **NCT ID:** NCT00282308
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-23
- **Primary completion:** 2008-01-31
- **Final completion:** 2012-05-28
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2017-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00282308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00282308, "A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00282308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*